2000/707/EC: Commission Decision of 6 November 2000 on financial assistance from the Community for storage in France, Italy and the United Kingdom of antigen for production of foot-and-mouth disease vaccine and amending Decision 2000/112/EC (notified under document number C(2000) 3175)
1. The Community shall grant France financial assistance for the stocking of antigen for production of foot-and-mouth disease vaccine.
2. The Laboratoire de pathologie bovine du Centre national d'études vétérinaires et alimentaires at Lyon in France shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply.
3. The Community's financial assistance shall be up to a maximum of EUR 30000 for the period 1 January to 31 December 2000.
1. The Community shall grant Italy financial assistance for the stocking of antigen for production of foot-and-mouth disease vaccine.
2. The Istituto Zooprofilattico Sperimentale di Brescia in Italy shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply.
3. The Community's financial assistance shall be up to a maximum of EUR 30000 for the period 1 January to 31 December 2000.
1. The Community shall grant the United Kingdom financial assistance for the stocking of antigen for production of foot-and-mouth disease vaccine.
2. The Institute for Animal Health at Pirbright in the United Kingdom shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply.
3. The Community's financial assistance shall be up to a maximum of EUR 15000 for the period 1 January to 30 June 2000.
1. The Community's financial assistance referred to in Article 1(3), Article 2(3) and Article 3(3) shall be paid following presentation, by the Member State concerned, of supporting documents, which demonstrate the effective completion of the tasks.
2. The supporting documents referred to in paragraph 1 must be presented to the Commission before 1 March 2001 and they should include:
(a) technical information on:
- the amount and type of antigen stored (storage records),
- storage equipment used (type, number and capacity of tanks),
- security system in place (temperature control, anti-theft measures),
- insurance arrangements (fire, accidents);
(b) financial information (completion of table as show in the Annex).
Articles 8 and 9 of Regulation (EC) No 1258/1999 shall apply mutatis mutandis.
In Article 3 of Decision 2000/112/EC the date of "1 February 2000" is changed to "1 July 2000".
This Decision is addressed to the Member States.
Done at Brussels, 6 November 2000.
For the Commission
David Byrne
Member of the Commission
(1) OJ L 224, 18.8.1990, p. 19.
(2) OJ L 160, 26.6.1999, p. 103.
(3) OJ L 368, 31.12.1991, p. 21.
(4) OJ L 301, 24.11.1999, p. 6.
(5) OJ L 33, 8.2.2000, p. 19.
(6) OJ L 33, 8.2.2000, p. 21.
Supplementary provisions
ANNEXSupplementary provisions
>PIC FILE= "L_2000289EN.004002.EPS">
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.
